logo
  • genedrive.com
  • About us
    • Company profile
    • Board of directors
    • Advisors
  • Our product
  • News & Events
    • Press releases
    • Events
    • Media
  • Careers
    • Careers
    • Applicants Privacy Notice
  • Investor relations
    • AIM Rule 26
    • Investor relations
    • Shareholders
    • Share price information
    • Regulatory news
    • Reports & presentations
    • Analyst notes
    • Constitutional documents
    • Investor news
    • Corporate governance
    • COVID 19
    • Investor contacts
    • Company information

Shareholders

Home > Investor relations > Shareholders

Identity and percentage holding of significant shareholders
 

Substantial holdings Shares held %
Calculus Capital 3,556,782 5.62%*
Global Health Investment Fund I, LLC 2,700,000 4.27%*
Spreadex Ltd 2,123,478 3.77%* **
Directors and related shareholders  
Ian Gilham 503,174 0.80%
David Budd 213,710 0.34%
Matthew Fowler 99,457 0.16%
Tom Lindsay 202,217 0.32%
Chris Yates 41,304 0.07%
Total Directors' holdings 1,059,862 1.68%
     
Total shares in issue 63,320,048 100.00%

* - DATE OF LAST NOTIFICATION
** - Note 494,425 of these shares are held via a CFD/Spreadbet

Shareholder information

genedrive shares are quoted and traded on the AIM market of the London Stock Exchange.

Authorised Share Capital: No authorised maximum number of shares are required. There are no shares held in treasury and there are no restrictions on transfer.

Issued Share Capital: The total number of genedrive plc ordinary shares of 1.5p each in issue is 63,320,048.

Number of AIM securities not in public hands is 12,829,644 or 22.7%.

Text updated:  28/09/2020

Latest reports

share price graph

30 March 2021

Interim Report and Accounts 31 December 2020

View all reports >

Investor News

Thursday January 01, 1970

Thursday January 01, 1970

Thursday January 01, 1970

View all news >

  • Privacy
  • Terms of use
  • Site map

© 2017-21 genedrive plc

genedrive plcThis site uses cookies for tracking and statistical purposes. Please read our privacy policy for more information.

Don't show this againclose